You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

MEGACE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Megace patents expire, and what generic alternatives are available?

Megace is a drug marketed by Bristol Myers Squibb and Endo Operations and is included in three NDAs. There are five patents protecting this drug.

The generic ingredient in MEGACE is megestrol acetate. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Megace

A generic version of MEGACE was approved as megestrol acetate by STRIDES PHARMA on August 8th, 1988.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for MEGACE?
  • What are the global sales for MEGACE?
  • What is Average Wholesale Price for MEGACE?
Drug patent expirations by year for MEGACE
Drug Prices for MEGACE

See drug prices for MEGACE

Recent Clinical Trials for MEGACE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1/Phase 2
Ontario Institute for Cancer ResearchPhase 1
Sunnybrook Health Sciences CentrePhase 1

See all MEGACE clinical trials

US Patents and Regulatory Information for MEGACE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb MEGACE megestrol acetate SUSPENSION;ORAL 020264-001 Sep 10, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Endo Operations MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Endo Operations MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Endo Operations MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb MEGACE megestrol acetate TABLET;ORAL 016979-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bristol Myers Squibb MEGACE megestrol acetate TABLET;ORAL 016979-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.